Qiming Venture Partners USA
Qiming Venture Partners USA is a healthcare venture capital firm that invests in early-stage biotech companies. It supports portfolio companies with operational expertise and networks spanning the US, China and broader Asia.
Facts
- HQ
- Seattle, Washington, US
- Founded
- 2017
- Employees
- 14
Is this your organization? Claim it
Seattle Immunotherapy Startup Umoja Biopharma Raises $100M Series C to Advance In Vivo CAR T-Cell Cancer Therapies
Seattle-based Umoja Biopharma raised $100 million in a Series C funding round to advance its CAR T-cell immunotherapy treatments, including an in vivo cell-generating technology for cancer. The company, founded in 2019 and led by CEO Andy Scharenberg, has programs in preclinical and Phase 1 stages and previously raised $263 million.
Icosavax files for IPO after raising $150M and advancing nanoparticle COVID-19 and RSV vaccines
Seattle-based Icosavax, a 2017 spinout from the University of Washington’s Institute for Protein Design, has filed for an IPO after raising over $150 million and advancing nanoparticle-based COVID-19 and RSV vaccine candidates into early clinical trials with support from a $10 million Gates Foundation grant.
Umoja Biopharma raises $210M Series B to advance in‑vivo T‑cell immunotherapies after $53M Series A seven months earlier
Umoja Biopharma, a Seattle-based immunotherapy startup, raised $210 million in a Series B just seven months after a $53 million Series A to advance in‑vivo T‑cell cancer therapies and tumor‑tagging technology into clinical trials for solid and hematological tumors.
See all 6 stories, episodes and videos about Qiming Venture Partners USA.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
Mark McDade Co-founder, Co Founder and Partner